Clinical Innovations hires Carl Rickenbaugh as VP of business development and strategy
April 29, 2019
Medical device industry veteran will accelerate company’s global M&A
strategy
SALT LAKE CITY–(BUSINESS WIRE)–Clinical
Innovations, one of the world’s largest medical device companies
focused on labor and delivery, as well as neonatal intensive care,
announced today it has hired Carl Rickenbaugh as vice president of
business development and strategy.
Rickenbaugh, a medical device industry veteran with decades of
experience building businesses through strategic acquisitions, will be
responsible for accelerating Clinical Innovations’ global M&A strategy.
He has served on boards of med-tech startups, and previously led
business development as Vice President of New Business Development at
Bard Peripheral Vascular, preceded by positions of increasing commercial
development responsibility at Abbott Laboratories.
“Continuing to grow through product acquisitions is critical to our
strategy, which directly leverages our expanding commercial
organization,” said Ken Reali, president and CEO of Clinical
Innovations. “Carl’s deep business development experience and proven
track record make him well-suited to help us advance those goals. We are
excited for Carl to join Clinical Innovations and bring a consistent
focus to our business development efforts.”
Clinical Innovations, with a presence in more than 90 countries, has
quickly expanded through numerous acquisitions and market entries in
recent years. Based in Salt Lake City and owned by leading investment
firm EQT, Clinical Innovations develops and manufactures market-leading
products such as the ROM Plus® Rupture of Membranes Test, traxi®
Panniculus Retractor, Kiwi® Vacuum-Assisted Delivery System and Koala®
Intrauterine Pressure Catheter. In 2018 alone, the company expanded
operations in France, China, Australia and the United States, furthering
the company’s ability to support its mission of helping mothers, babies
and the physicians who treat them.
“Clinical Innovations has succeeded because of its talented employees,
industry-leading products and sound strategy,” Rickenbaugh said. “I’m
honored to be joining the team and look forward to building on its
strong M&A momentum.”
Rickenbaugh holds a bachelor’s and a master’s degree from the University
of Cincinnati and an MBA from Georgetown University.
About Clinical Innovations
Clinical Innovations is one of the largest medical device companies
exclusively focused on labor and delivery and neonatal intensive care.
The company is a market-leader in several categories with products such
as the Koala® Intrauterine Pressure Catheter, Kiwi® Vacuum-Assisted
Delivery System, ROM Plus® Rupture of Membranes Test, traxi® Panniculus
Retractor, ClearView® Uterine Manipulator and the babyLance™ Safety heel
stick. Clinical Innovations is expanding its global presence while
directly researching and developing state-of-the-art technologies and
innovative medical devices that fulfill its mission of improving the
lives of mothers and their babies throughout the world. Clinical
Innovations is an EQT portfolio company. For more information, visit clinicalinnovations.com.
About EQT
EQT is a leading investment firm with approximately EUR 61 billion in
raised capital across 29 funds. EQT funds have portfolio companies in
Europe, Asia and the U.S. with total sales of more than EUR 19 billion
and approximately 110,000 employees. EQT is an active investor and owner
in the health care sector, including investments in Certara, Press
Ganey, Ottobock, Sivantos, and Lima. EQT works with portfolio companies
to achieve sustainable growth, operational excellence and market
leadership. For more information, visit EQTpartners.com.
Contacts
Ashley Dennison, Aileron Communications
303.552.7460, adennison@aileroninc.com